qiagen is the leading global provider of sample to insight solutions to transform biological materials into valuable molecular insights. qiagen sample technologies isolate and process dna, rna and proteins from blood, tissue and other materials. assay technologies make these biomolecules visible and ready for analysis. bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. automation solutions tie these together in seamless and cost-effective molecular testing workflows. qiagen provides these workflows to more than 500,000 customers around the world in molecular diagnostics (human healthcare), applied testing (forensics, veterinary testing and food safety), pharma (pharmaceutical and biotechnology companies) and academia (life sciences research). as of june 30, 2015, qiagen employed approximately 4,400 people in over 35 locations worldwide. further information can be found at http://www.qiagen.com.
Company profile
Ticker
QGEN
Exchange
Website
CEO
Thierry Bernard
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
QIAGEN NV
SEC CIK
QGEN stock data
Latest filings (excl ownership)
IRAN
Disclosure regarding Iran Threat Reduction and Syria Human Rights Act
8 Mar 24
20-F
2023 FY
Annual report (foreign)
8 Mar 24
6-K
Current report (foreign)
8 Feb 24
6-K
QIAGEN announces details for completion of synthetic share repurchase of up to approximately $300 million
23 Jan 24
6-K
QIAGEN announces plans to return approximately $300 million to shareholders
8 Jan 24
6-K
Current report (foreign)
31 Oct 23
6-K
Current report (foreign)
31 Oct 23
6-K
Notice of the Annual General Meeting of Shareholders
31 Oct 23
6-K
Current report (foreign)
9 Aug 23
6-K
Current report (foreign)
9 Aug 23
Transcripts
QGEN
Earnings call transcript
2023 Q4
7 Feb 24
QGEN
Earnings call transcript
2023 Q3
31 Oct 23
QGEN
Earnings call transcript
2023 Q2
9 Aug 23
QGEN
Earnings call transcript
2023 Q1
4 May 23
QGEN
Earnings call transcript
2022 Q4
8 Feb 23
QGEN
Earnings call transcript
2022 Q3
8 Nov 22
QGEN
Earnings call transcript
2022 Q2
29 Jul 22
QGEN
Earnings call transcript
2022 Q1
28 Apr 22
QGEN
Earnings call transcript
2021 Q4
9 Feb 22
QGEN
Earnings call transcript
2021 Q3
4 Nov 21
Latest ownership filings
SC 13G/A
MASSACHUSETTS FINANCIAL SERVICES CO /MA/
9 Feb 24
SC 13G/A
BlackRock Inc.
23 Jan 24
SC 13G/A
MASSACHUSETTS FINANCIAL SERVICES CO /MA/
6 Dec 23
144
Notice of proposed sale of securities
25 Aug 23
SC 13G/A
MASSACHUSETTS FINANCIAL SERVICES CO /MA/
8 Feb 23
SC 13G/A
BlackRock Inc.
23 Jan 23
SC 13G/A
MASSACHUSETTS FINANCIAL SERVICES CO /MA/
2 Feb 22
SC 13G/A
BlackRock Inc.
27 Jan 22
SC 13G
BlackRock Inc.
26 Jan 22
SC 13G/A
MASSACHUSETTS FINANCIAL SERVICES CO /MA/
11 Feb 21
Financial summary
Quarter (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q3 2023
56.1% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 276 |
Opened positions | 33 |
Closed positions | 33 |
Increased positions | 100 |
Reduced positions | 102 |
13F shares | Current |
---|---|
Total value | 5.10 tn |
Total shares | 128.03 mm |
Total puts | 175.10 k |
Total calls | 415.45 k |
Total put/call ratio | 0.4 |
Largest owners | Shares | Value |
---|---|---|
Massachusetts Financial Services | 22.26 mm | $901.41 bn |
Vanguard | 8.73 mm | $353.65 bn |
BLK Blackrock | 7.49 mm | $303.43 bn |
Wellington Management | 6.05 mm | $245.30 bn |
Amundi | 5.89 mm | $226.52 bn |
FIL | 4.70 mm | $190.14 bn |
Point72 Asset Management | 4.38 mm | $177.34 bn |
DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main | 3.46 mm | $140.00 bn |
DekaBank Deutsche Girozentrale | 3.39 mm | $137.20 bn |
DB Deutsche Bank AG - Registered Shares | 3.35 mm | $135.54 bn |
News
QIAGEN Expands Tuberculosis Portfolio With New NGS Panel To Support Real-Time Surveillance And Combat Antimicrobial Resistance
24 Apr 24
QIAGEN Partners With International Panel Physicians Association To Increase Awareness Of Tuberculosis Screening Requirements
18 Mar 24
JP Morgan Maintains Overweight on Qiagen, Raises Price Target to $52
8 Feb 24
Citigroup Maintains Buy on Qiagen, Lowers Price Target to $60
8 Feb 24
QIAGEN Sees FY24 EPS $2.10 CER Vs $2.20 CER Est.; Revenue Of At Least $2B CER Vs 2.06B CER Est.
6 Feb 24
Press releases
QIAGEN expands tuberculosis portfolio with new NGS Panel to support real-time surveillance and combat antimicrobial resistance
24 Apr 24
QIAGEN N.V. to release results for Q1 2024 and hold webcast
9 Apr 24
QIAGEN strengthens its portfolio for cancer research, showcasing latest product launches at AACR Annual Meeting 2024
3 Apr 24
QIAGEN introduces QIAstat-Dx Analyzer 2.0 with remote test results access, enhancing collaboration across healthcare system
25 Mar 24
QIAGEN partners with International Panel Physicians Association to increase awareness of tuberculosis screening requirements
18 Mar 24